45 results about "Plaque rupture" patented technology

A computer system and method are disclosed for automatically generating a vascular model of a blood vessel to support, for example, identification of mechanical factors corresponding to the blood vessel. The method includes interpolating data points corresponding to a contour of the blood vessel; generating a structural model representing three-dimensional structural characteristics of the blood vessel based on interpolated contours; generating a fluid model representing three-dimensional characteristics of fluid flow within the vessel; and generating a vascular model based on the structural model and the fluid model. The method may also include performing a mechanical analysis of the vascular model to identify a mechanical factor associated with the vessel, for example, a factor associated with a potential plaque rupture within the vessel. Embodiments of the invention are applicable to the diagnosis, assessment, or treatment of cardiovascular diseases.

A computer system and method are disclosed for automatically generating a vascular model of a blood vessel to support, for example, identification of mechanical factors corresponding to the blood vessel. The method includes interpolating data points corresponding to a contour of the blood vessel; generating a structural model representing three-dimensional structural characteristics of the blood vessel based on interpolated contours; generating a fluid model representing three-dimensional characteristics of fluid flow within the vessel; and generating a vascular model based on the structural model and the fluid model. The method may also include performing a mechanical analysis of the vascular model to identify a mechanical factor associated with the vessel, for example, a factor associated with a potential plaque rupture within the vessel. Embodiments of the invention are applicable to the diagnosis, assessment, or treatment of cardiovascular diseases.

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and / or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

The invention provides a method and a system for obtaining a four-dimensional blood vessel deformation behavior and in-vivo stress of a blood vessel wall. The method combines a three-dimensional image reconstruction technology and a discrete approximation theory to realize the big deformation behavior and the in-vivo stress of the blood vessel wall. The innovations of the invention are that the change of an anatomic form of healthy or pathological vessels in a cardiac cycle along with the time can be intuitively researched for a stent to intervene pre-operation evaluation and selection of a treatment strategy; a change condition of the in-vivo stress distribution of the blood vessel wall can be also provided for plaque rupture prediction and diagnosis, so that a new method is provided for quantitative description of kinematics characteristics of the blood vessel wall and the in-vivo stress of the blood vessel wall.

The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia.

The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia.

Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of disorders such as cancer, Crohn's disease, arthritis, atherothrombosis and plaque rupture are also provided.

Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Closbidium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, acute pancreatitis, psoriasis, infertility and allergic disorders such as rhinitis, conjunctivitis, and urticaria.

Devices and methods for extracting core material contained in plaque deposits inside a blood vessel are presented. A device in accordance with one embodiment of the invention includes a catheter having an elongate shaft, a collection array of a plurality of collection lumens disposed about the distal portion of the elongate shaft, a means for radially extending and / or collapsing the collection array, and a suction means for extracting material from the lumen of the blood vessel. A method in accordance with one embodiment of the present invention includes the steps of inserting the distal portion of the catheter into a lumen of the blood vessel, positioning the distal end of the collection array proximate plaque deposits, extending the collection array to rupture the plaque deposits and urging core material therefrom, and extracting the material using a suction means fluidly coupled to the proximal end of the collection array.

A pharmaceutical composition is provided for treatment and / or prevention of a disease, a disorder and / or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and / or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt or a hydrate thereof and Pitavastatin, and a pharmaceutically acceptable carrier, wherein the agent is intended to be simultaneously administered, or separately administered with interval of time to a patient in need thereof. There is also to provide a method for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and / or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion, comprising simultaneously administering, or separately administering with interval of time an effective amount of the compound 1, its pharmaceutically acceptable salt or a hydrate thereof and an effective amount of Pitavastatin to a patient in need thereof.

A balloon catheter construction for percutaneous use is provided employing a balloon polymer material bonded to an introducer shaft with a bonding agent comprising a low molecular weight oligomer corresponding to the higher molecular weight polymer of the balloon. The oligomer functions alone or together with a primer which enables bonding to the shaft during heat curing, thereby securing the balloon thereon. The balloon introducer catheter is designed to effectively block emboli material which are released from say a plaque rupture, or other site and to then to remove such material by suction from a blood vessel such as a vein or artery.

This invention is the coadministration of ACAT and MMP inhibitors for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal.

Atherosclerosis can be viewed as a response to injury and it is not atherosclerosis per se that is serious but instead factors leading to rupture of atherosclerotic plaques. In the present invention we have identified such factors. A decreased binding of Annexing V to the endothelium was seen in patients with a history of atherothrombosis. The use of native Annexin V or an N-terminal fragment as an active component or a subfraction of immunoglobulins to manufacture a pharmaceutical composition is proposed to improve said binding. The use of Annexin V, N-terminal fragments or immunoglobulins to increase the Annexin V-binding to carotid plaque represents novel mechanism for preventing atherothrombosis.

The invention discloses a construction method of an atherosclerosis vulnerable plaque mouse model. According to the method, a low-density lipoprotein receptor gene (LDLR) with heterozygous point mutation in a fibrillin-1 (Fbn1) gene is obtained through a hybridization method to knock out a mouse. According to the method, Fbn1C1039G+ / - point mutation is introduced into an LDLR- / - mouse genome for the first time, characteristics of two genotypes are combined, the method is simple and easy to implement, and vulnerable plaques with large lipid cores, a large number of inflammatory cells, typical thin fibrous caps, rich new blood vessels and the characteristics of plaque internal hemorrhage, vascular outward reconstruction and the like can be formed; the occurrence of acute cardiovascular and cerebrovascular events such as plaque rupture similar to that of the human body can be observed on the model. The method is high in model forming rate and good in repeatability, a good animal foundation is provided for medicine research and instrument consumable improvement, and a good platform is provided for exploring an atherosclerosis mechanism.

A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.

The invention discloses a vascular plaque risk prediction method, device and equipment and a medium, and the method comprises the steps: obtaining an original medical image of a user's blood vessel, and generating a blood vessel model of the user's blood vessel according to the original medical image; determining hemodynamic parameters of blood vessels of the user according to the blood vessel model; and predicting plaque risk information of the blood vessel of the user based on the hemodynamic parameters, wherein the plaque risk information comprises a plaque growth risk and a plaque rupture risk. The hemodynamic parameters of the user blood vessel can be accurately calculated through the blood vessel model generated based on the original medical image of the user blood vessel, and the plaque growth risk and the plaque rupture risk of the user blood vessel are evaluated based on the hemodynamic parameters to obtain the plaque risk information of the user blood vessel, and the plaque in the blood vessel of the user is effectively monitored according to the growth and rupture conditions of the plaque in the plaque risk information.

Disclosed are medical devices and methods for the local delivery and treatment of vascular conditions. The methods and treatments involve local delivery of at least one matrix metalloproteinase inhibitor. The vascular conditions described herein include plaque rupture, aneurysm, stenosis, restenosis, atherosclerosis and combinations thereof.

The invention provides a multi-dimensional plaque rupture risk early-warning system, wherein an acquired CCTA easy-damage plaque automatic identification method is combined with CT real-time blood flow dynamics analysis technology based on deep learning, thereby creating a noninvasive plaque rupture risk early-warning model with higher efficiency, higher sensitivity and higher accuracy, and supplying a comprehensive and reliable basis and a key technical means for intelligent noninvasive accurate detection and early warning of coronary artery plaque rupture.

The invention discloses a method for cultivating an edible fungus of xiuzhen genus, relating to edible fungi. Cultivate the parent species of edible fungus PDA with PDA slant medium. The original species uses wheat grains as the substrate. After the wheat grains are soaked in water, calcium carbonate is added for inoculation and cultivation; Inoculate when the temperature in the cultivation bag drops to 23-26°C, and then place the cultivation bag in the cultivation room for cultivation. When the strain germinates and the mycelium grows to half the height of the cultivation bag, the buckle of the bag is loosened; when the temperature is lower than 20°C, add Temperature to 23-26°C, after 30-40 days of cultivation, after the mycelia are covered with the cultivation bag, it enters the physiological maturity stage, that is, the bag is opened, and then sprayed with water after covering the soil; after 7-10 days after covering the soil, the white mycelia crawls On the soil surface, after the soil surface is covered with thick white hyphae, stop spraying water, control the relative humidity of the air at 85% to 95%, and control the cultivation temperature at 20 to 30°C. Harvesting is suitable when the fungus film has not yet ruptured and opened the umbrella.

The invention relates to a stent for a blood vessel. The stent comprises a coating film and an anchoring piece which are connected with each other, the anchoring piece is used for fixing the coating film in the blood vessel; the coating film is used for covering the diseased region of the blood vessel. The anchoring piece of the stent is used for better attaching the coating film to the vascular intima and fixing the coating film at an expected implantation position when the stent is scoured by blood, the coating film can hold unstable plaques on the vascular intima and prevent the unstable plaques from being broken; meanwhile, the coating film can trigger foreign body reaction in a living body, so that vascular endothelial growth is stimulated. Unstable plaques grow into stable plaques, and the occurrence rate of acute thrombus is reduced. The stent can also be used for treating vascular tearing in the interventional process, and thrombus events caused by falling of the torn vascular wall are avoided.

The invention discloses a simplified calculation method based on coronary artery multimode image crack formation and expansion and a plaque fracture risk quantification evaluation system, and the method comprises the steps: obtaining multimode images, such as coronary artery angiography images and intracavity images (such as optical coherence tomography), through an image input module; respectively segmenting and registering interested blood vessels or plaques on different images by adopting an image processing technology, and quantitatively obtaining anatomical indexes of lesion coronary plaques; and further calculating the distribution of the dynamic indexes of the superficial wall based on time sequence coronary angiography and determining a relatively high-risk position along the longitudinal direction of the blood vessel so as to obtain a fatigue risk coefficient formed by the local crack of the superficial wall. According to the method, the anatomical indexes of the coronary artery multi-modal image are combined, and the quantitative assessment of the crack formation based on the superficial surface of the coronary artery and the plaque crack propagation risk based on the cross section image are further added, so that the plaque fracture process is assessed more completely and comprehensively.

Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.

The invention provides application of a reagent in the preparation of a kit; the kit is used for diagnosing acute coronary syndrome; the reagent is used for detecting at least one of miR-155-5p, miR-483-5p, and miR-451a. The inventor discovers through experiments that miR-155-5p, miR-483-5p or miR-451a has significant expression differences before and after plaque rapture, and has good diagnostic value in the early diagnosis for the rapture of coronary plaque; the kit prepared with the reagent for detecting at least one of miR-155-5p, miR-483-5p, and miR-451a is effectively applicable to the early diagnosis of the rupture of coronary plaque, and has the advantages of high sensitivity and high specificity.

The invention discloses a simplified calculation method based on the formation and expansion of coronary multi-mode image cracks and an evaluation system for quantifying the risk of plaque rupture, which acquires coronary angiography images and intracavity images (such as optical coherence tomography) through an image input module Using image processing technology to segment and register interested blood vessels or plaques on different images, and quantitatively obtain the anatomical indexes of diseased coronary plaques, and further calculate superficial plaques based on time-series coronary angiography The distribution of wall dynamics indices and the determination of relatively high-risk locations along the longitudinal direction of the vessel to obtain the fatigue risk factor for localized crack formation in the superficial wall. The present invention combines the anatomical indicators of coronary multimodal images, and further increases the quantitative assessment of the risk of plaque crack expansion based on superficial coronary crack formation and cross-sectional images, so as to evaluate plaque more completely and comprehensively. rupture process.

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, advanced atherosclerosis / plaque rupture, ischemia / reperfusion, hypertension, restenosis, cardiac calcification, allo / xenograft valvular calcifications, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and / or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. Moreover, the present invention is further based in part on the generation and phenotypic characterization of transgenic knockout homozygous rchd534 mutant mice which display characteristic cardiovascular disease symptoms. Such transgenic knockout homozygous rchd534 mutant mice are useful models for the analysis and characterization of rchd534 protein involvement in development and homeostasis of the cardiovascular system and tissue-specific regulation of the TGF-beta signaling pathways.

The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.